The FDA has granted AstraZeneca approval for its Bydureon pen, 2 milligrams, to help bolster glycemic control in adult type 2 diabetes patients. The pen is to be used as an add-on to diet and exercise.
Published in Brief:
|President/Chief Executive Officer||
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Director, Payer Marketing||
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Chief Medical Officer, Texas Children's Health Plan||
Cejka Executive Search for Texas Childre's Health Plan